Browse the evidence

Individual variability in exercise-induced weight loss is significant, with some individuals losing very little weight ('non-responders') despite high adherence, often due to compensatory increases in energy intake or changes in food preference.

If you exercise consistently but don't lose much weight, don't stop. You are likely still improving your cardiovascular health and body composition. This is common and does not mean the exercise was wasted.

Psychological traits, specifically high Disinhibition and low Restraint, are associated with greater compensatory eating and poorer weight loss outcomes following exercise.

If you struggle with impulsive eating, exercise might help you gain better control over your food choices over time. Focus on building self-restraint, as this is linked to better weight loss results from exercise.

Macronutrient composition (high-carb/low-fat, high-fat/low-carb, or high-protein) has no significant independent effect on long-term weight loss compared to isocaloric diets when behavioral adherence and caloric deficit are controlled.

Stop searching for the 'perfect' macronutrient ratio (keto, low-fat, high-protein). The specific type of diet matters less than your ability to stick to a caloric deficit. Focus on behavioral strategies, counseling, and sustainable habits rather than restricting specific food groups, as all diets yield similar modest weight loss (3-4 kg) over 2 years if adherence is maintained.

Early Time-Restricted Eating (eTRE) with an 8-hour window (8 am - 4 pm) does NOT produce significantly greater weight loss than a calorie-restricted Mediterranean diet (MedDiet) in adults with obesity.

Early time-restricted eating (8 am - 4 pm) with a 600-calorie deficit did not result in significantly greater weight loss than a standard Mediterranean diet in this study. You may not see extra benefits from this specific timing strategy.

The food industry actively undermines public health dietary advice and government nutrition guidelines to protect market share for processed, calorie-dense products.

Be skeptical of health claims on processed food packaging. Recognize that marketing strategies are designed to increase consumption, not necessarily to improve health. Prioritize whole, unprocessed foods and read ingredient lists critically.

Food industry lobbying and legal strategies have successfully deregulated dietary supplements and weakened the FDA's ability to restrict false health claims.

Do not assume supplements are proven to work just because they are sold in stores. Look for third-party verification seals and consult a healthcare provider before starting any new supplement regimen.

Weight stigma and discrimination are significant behavioral and emotional mechanisms linking high body weight to psychological distress.

Recognize that weight stigma is a real and harmful social force, not a personal failing. Seek supportive environments and mental health resources that address the impact of discrimination.

Global sugar-sweetened beverage (SSB) intake among adults increased by 16% (0.37 servings/week) between 1990 and 2018, with the most dramatic increases occurring in Sub-Saharan Africa (+81.9%) and specific high-population countries like Nigeria and Ethiopia.

Track your weekly SSB servings. If you live in or travel to regions with rapidly rising intake (like Sub-Saharan Africa or parts of Asia), be aware that marketing is aggressively targeting these demographics. Aim to keep added sugars <5-10% of daily calories as recommended by national guidelines.

Standard anti-diabetic treatments often fail to achieve recommended cardiometabolic targets (HbA1c, BP, LDL) in real-world clinical settings, leaving most patients with uncontrolled risk factors.

If you are taking medication for diabetes, do not assume your health is fully managed. This study found that less than 25% of treated patients achieved optimal levels for blood sugar, blood pressure, and cholesterol. You must actively manage your weight and lifestyle alongside your medication to truly control your risk.

A diagnosis of Type 2 Diabetes acts as a 'teachable moment' that significantly accelerates smoking cessation compared to the general population, but fails to trigger positive changes in physical activity, alcohol consumption, or fruit and vegetable intake.

Getting a Type 2 Diabetes diagnosis is a strong motivator to quit smoking, but it rarely changes your diet or exercise habits on its own. Do not rely on the diagnosis to fix your lifestyle. You must actively implement specific plans for nutrition and physical activity, as these habits are resistant to change without targeted intervention.

Social media promotion and celebrity endorsements of semaglutide (specifically Ozempic/Wegovy) for off-label weight loss directly drive global search interest and subsequent supply shortages, overriding regulatory approval timelines.

Search interest in weight loss drugs like semaglutide is currently driven more by social media trends and celebrity endorsements than by official medical approvals. If you are seeing a surge in interest or shortages, it is likely due to viral media content rather than a change in medical guidelines.

The same mHealth intervention does NOT produce statistically significant reductions in systolic or diastolic blood pressure four years after completion, nor does it significantly reduce the incidence of hypertension, although a non-significant trend toward reduced hypertension risk was observed in high-adherence subgroups.

Do not expect this mobile health program to significantly lower your blood pressure, even if it helps you lose weight. The study showed no significant change in systolic or diastolic blood pressure four years after the intervention. However, the weight loss achieved is still a valuable health outcome, and you should continue to monitor your blood pressure with your healthcare provider.

Individual demographic and socioeconomic factors explain the majority of spatial clustering in extreme BMI values among adults with diabetes, whereas neighborhood environmental factors (food access, deprivation) explain a significantly smaller portion.

If you are managing diabetes and weight, your personal socioeconomic situation and personal choices are stronger predictors of your BMI clustering than the specific food stores or walkability of your immediate neighborhood. While improving neighborhood access is good, focusing on individual-level factors (income, education, personal habits) is likely to have a larger impact on your weight status than relying solely on environmental changes.

Point-of-care gastric ultrasound is an effective and objective method to assess gastric contents and guide anesthetic management for patients on GLP-1 agonists.

Anesthesiologists should consider using gastric ultrasound to check the stomach contents of patients on GLP-1 agonists before surgery. This helps decide whether to proceed with anesthesia or take extra precautions to prevent aspiration.

Brief lifestyle interventions delivered by generalist community nurses increase client recall of advice and referrals but do not significantly change actual lifestyle behaviors or weight.

If you are a community nurse or healthcare provider, offering brief lifestyle advice is a good start, but it is not enough to change health outcomes on its own. You must actively refer high-risk clients to more intensive, long-term lifestyle programs to see real changes in diet, activity, or weight. Simply giving advice without a pathway to sustained support will not work.

A 12-week self-guided resistance training program does not significantly improve muscle strength or muscle mass in women with generalized joint hypermobility (GJH).

If you have generalized joint hypermobility, simply doing resistance exercises twice a week on your own is unlikely to build strength or muscle. You likely need higher intensity (heavier loads) and direct supervision to ensure proper progression and safety.

Intentional weight loss in individuals with Type 2 Diabetes (T2D) is not consistently associated with reduced mortality risk and may be associated with higher mortality in obese subgroups, whereas weight cycling (body weight variability) is consistently associated with significantly increased all-cause and cardiovascular disease mortality.

If you have Type 2 Diabetes, do not focus on weight loss as a primary goal for reducing mortality risk. Instead, prioritize increasing physical activity and improving cardiorespiratory fitness. Weight cycling (losing and regaining weight) is associated with higher mortality risk, so maintaining a stable weight while improving fitness is a safer and more effective strategy for longevity.

There is a significant disparity in medication initiation rates between diabetes and obesity indications, with 72.2% of diabetes prescriptions filled within 60 days compared to only 46.8% of obesity prescriptions.

If you are prescribed a GLP-1 for weight loss, be aware that you are less likely to fill the prescription than someone prescribed for diabetes. This is due to insurance coverage gaps, not a lack of desire to treat. Check your coverage status before the prescription is written to avoid delays.

High out-of-pocket costs for semaglutide create a socioeconomic barrier to access, resulting in significantly lower prescription rates among low-income individuals despite them having a higher prevalence of obesity.

If you are on a limited budget, the high out-of-pocket cost of semaglutide may prevent you from accessing it, even if you have obesity. This is a systemic issue where low-income individuals are undertreated. Advocacy for reimbursement or subsidies is needed to address this inequality.

Significant inequities exist in access to bariatric surgery in Australia, with lower rates in public hospitals, rural areas, and among males, despite similar or higher obesity prevalence in these groups.

Access to bariatric surgery in Australia is uneven, with rural residents, men, and those without private healthcare facing significant barriers. If you live in a rural area or are a man, be proactive in seeking information and support to overcome these barriers. Explore public sector options and discuss your specific situation with a healthcare provider.

A 12-month behavioral weight maintenance intervention following weight loss fails to provide long-term metabolic or weight benefits beyond the intervention period, as benefits disappear after the maintenance phase ends.

A one-year maintenance program after weight loss will not prevent long-term weight regain or metabolic decline once you stop the program. To maintain results, you likely need a strategy of repeated short-term interventions or continuous lifestyle management, as a single fixed-duration maintenance phase is insufficient for long-term success.

Diet and lifestyle interventions alone are insufficient for long-term obesity management, as they typically result in only ~3% sustained weight loss at 5 years and fail to reverse population-level obesity trends.

Do not rely on short-term diet and exercise programs for long-term weight control. The average outcome is minimal sustained loss (~3%). Recognize obesity as a chronic condition requiring long-term, multidisciplinary support (medical, behavioral, environmental) rather than a finite 'program' you complete.

Positive Airway Pressure (PAP) therapy, while effective for reducing AHI and improving symptoms, has not demonstrated a benefit on composite cardiovascular endpoints in randomized controlled trials.

PAP is the standard treatment for OSA and effectively reduces breathing interruptions and daytime sleepiness. However, it does not appear to reduce long-term cardiovascular risks like heart attacks or strokes in large studies, and many patients struggle with adherence due to discomfort. It remains a good option for symptomatic relief and blood pressure control, but may not be a 'one-size-fits-all' solution.

Discontinuation of GLP-1 receptor agonists (GLP-1 RA) is significantly higher and reinitiation is significantly lower in patients without type 2 diabetes (T2D) compared to those with T2D, driven largely by insurance coverage and cost barriers rather than efficacy.

If you are taking a GLP-1 RA for weight loss without diabetes, be aware that insurance coverage is a major hurdle. Discontinuation rates are significantly higher for non-diabetics, often due to cost. If you face financial barriers, discuss coverage options or assistance programs with your provider immediately, as these factors heavily influence long-term adherence.